Home › Investor Relations › Press Releases

Press Releases

All 2010 Releases
	Santarus Extends Maturity of $25 Million Revolving Line of Credit to July 2013 Aug 30, 2010	11.5 KB
	SAN DIEGO, Aug 30, 2010 (BUSINESS WIRE) -- Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that it has extended the maturity date of its $25 million revolving line of credit with Comerica Bank from July 11, 2011 to July 11, 2013. Santarus makes interest-only payments on any draws ... Read more
	Santarus Reports Second Quarter 2010 Financial Results Aug 2, 2010	26.5 KB
	SAN DIEGO, Aug 02, 2010 (BUSINESS WIRE) -- Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today reported financial and operating results for the quarter ended June 30, 2010. Key financial results include: Product-related revenue of $41.0 million increased approximately 22%, compare... Read more
	Santarus to Present at BMO Capital Markets 10th Annual Focus on Healthcare Conference Jul 28, 2010	11.1 KB
	SAN DIEGO, Jul 28, 2010 (BUSINESS WIRE) -- Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, today announced that Gerald T. Proehl, president and chief executive officer, will make a presentation at the BMO Capital Markets 10th Annual Focus on Healthcare Conference on Thursday, August 5, 2010 at 2:... Read more
	Santarus to Hold Second Quarter 2010 Financial Results Conference Call on August 2 Jul 26, 2010	11.5 KB
	SAN DIEGO, Jul 26, 2010 (BUSINESS WIRE) -- Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that it will release second quarter 2010 financial results after market close on Monday, August 2, 2010. Santarus management will host an investment-community conference call at 5:00 p.m. E... Read more
	Santarus Announces Launch of Prescription ZEGERID Authorized Generic and Company Restructuring Jun 30, 2010	13.0 KB
	SAN DIEGO, Jun 30, 2010 (BUSINESS WIRE) -- Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that pursuant to its distribution and supply agreement with Prasco, LLC, Prasco is commencing shipments of an authorized generic of prescription ZEGERID(R) (omeprazole/ sodium bicarbonate) ... Read more
	New Clinical Study Shows Patients With Type 2 Diabetes May be Able to Tolerate Higher Doses of Metformin Using Glumetza Jun 28, 2010	61.2 KB
	MENLO PARK and SAN DIEGO, Calif. (June 28, 2010) - Depomed, Inc. (NASDAQ:DEPO) and Santarus, Inc. (NASDAQ:SNTS) today announced new data suggesting that patients previously intolerant of metformin may be able to tolerate higher doses of metformin when treated with GLUMETZA® (metformin HCl extended release tablets). The findings [abstr... Read more
	Santarus Begins Enrollment in Phase III Clinical Program for Rifamycin SV MMX in Travelers' Diarrhea Jun 2, 2010	14.1 KB
	SAN DIEGO, Jun 02, 2010 (BUSINESS WIRE) -- Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, today announced that is has begun to enroll patients in the first study in its Phase III clinical program to evaluate the efficacy and safety of rifamycin SV MMX(R) for the treatment of patients with travel... Read more
	Santarus to Present at the Jefferies 2010 Global Life Sciences Conference May 28, 2010	11.3 KB
	SAN DIEGO, May 28, 2010 (BUSINESS WIRE) -- Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, today announced that Gerald T. Proehl, president and chief executive officer, will make a presentation at the Jefferies 2010 Global Life Sciences Conference on Tuesday, June 8, 2010, at 11:00 a.m. Eastern time ... Read more
	Santarus Reports First Quarter 2010 Financial Results May 6, 2010	23.9 KB
	SAN DIEGO, May 06, 2010 (BUSINESS WIRE) -- Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today reported financial and operating results for the quarter ended March 31, 2010. Key financial results for the 2010 first quarter include: Net income of $3.3 million, or $0.05 per diluted share, inc... Read more
	Santarus to Hold First Quarter 2010 Financial Results Conference Call on May 6 Apr 28, 2010	11.6 KB
	SAN DIEGO, Apr 28, 2010 (BUSINESS WIRE) -- Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, today announced that it will release first quarter 2010 financial results after market close on Thursday, May 6, 2010. Santarus management will host an investment-community conference call at 5:00 p.m. Eastern ... Read more
	Santarus Announces District Court Ruling in Par Litigation Apr 14, 2010	11.6 KB
	SAN DIEGO, Apr 14, 2010 (BUSINESS WIRE) -- Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, today announced that the U.S. District Court for the District of Delaware has ruled that five patents covering Santarus' ZEGERID(R) (omeprazole/sodium bicarbonate) prescription products are invalid due to o... Read more
	Santarus Announces Launch of ZEGERID OTC by Schering-Plough Consumer HealthCare Apr 1, 2010	16.4 KB
	SAN DIEGO, Apr 01, 2010 (BUSINESS WIRE) -- Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, today announced that Schering-Plough HealthCare Products, Inc., the consumer healthcare subsidiary of Merck & Co., Inc., has commenced promotion of ZEGERID OTC(TM) (omeprazole 20 mg/sodium bicarbonate 1100 ... Read more
	Santarus Announces Completion of Enrollment in U.S. Phase III Clinical Study for Budesonide MMX Mar 25, 2010	13.2 KB
	SAN DIEGO, Mar 25, 2010 (BUSINESS WIRE) -- Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced the completion of enrollment of 510 patients in a U.S. Phase III clinical study to evaluate budesonide MMX(R) administered over eight weeks for the induction of remission of mild or moderat... Read more
	Santarus Reports Fourth Quarter and Full Year 2009 Financial Results Mar 3, 2010	26.5 KB
	SAN DIEGO, Mar 03, 2010 (BUSINESS WIRE) -- Santarus, Inc. (NASDAQ:SNTS), a specialty biopharmaceutical company, today reported financial and operating results for the quarter and full year ended December 31, 2009. Key financial results for the 2009 fourth quarter: Product-related revenue of $38.9 million compared... Read more
	Santarus to Present at March Investment Conferences Feb 25, 2010	11.7 KB
	SAN DIEGO, Feb 25, 2010 (BUSINESS WIRE) -- Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that Gerald T. Proehl, president and chief executive officer, will make presentations at the following investment conferences: The Cowen and Company 30th Annual Health Care Conference on... Read more
	Santarus to Hold Fourth Quarter and Full Year 2009 Financial Results Conference Call on March 3 Feb 17, 2010	11.6 KB
	SAN DIEGO, Feb 17, 2010 (BUSINESS WIRE) -- Santarus, Inc. (NASDAQ: SNTS), a specialty biopharmaceutical company, today announced that it will release fourth quarter and full year 2009 financial results after market close on Wednesday, March 3, 2010. Santarus management will host an investment-community conference call at ... Read more
2010 \| 2009 \| 2008 \| 2007 \| 2006

=add release to Briefcase